DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Miller T, Habek M, Coles AJ , et al.
Analysis of data from RRMS alemtuzumab-treated patients in the clinical program to evaluate incidence rates of malignancy.
Poster presented at: 30th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; September 10–13, 2014; Boston, MA
We do not assume any responsibility for the contents of the web pages of other providers.